lupus nephritis
Information
- Disease name
- lupus nephritis
- Disease ID
- DOID:0080162
- Description
- "A glomerulonephritis that is characterized by inflammation of the kidneys resulting from systemic lupus erythematosus." [url:https\://en.wikipedia.org/wiki/Lupus_nephritis#cite_note-1, url:https\://medlineplus.gov/ency/article/000481.htm]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02630628 | Active, not recruiting | Phase 4 | Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis | December 5, 2015 | January 31, 2025 |
| NCT04522505 | Active, not recruiting | Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis | November 29, 2017 | May 24, 2024 | |
| NCT04221477 | Active, not recruiting | Phase 3 | A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis | August 10, 2020 | February 28, 2029 |
| NCT04643470 | Active, not recruiting | Phase 2 | Zanubrutinib in Participants With Active Proliferative Lupus Nephritis | December 22, 2020 | September 2024 |
| NCT05432531 | Active, not recruiting | Phase 3 | Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis | June 1, 2022 | April 1, 2023 |
| NCT05704088 | Active, not recruiting | Phase 4 | SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients | October 8, 2022 | December 8, 2023 |
| NCT05748925 | Active, not recruiting | Phase 4 | Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients | October 1, 2022 | December 1, 2023 |
| NCT03453619 | Active, not recruiting | Phase 2 | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | January 22, 2018 | December 2023 |
| NCT00302549 | Completed | N/A | To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN | May 2004 | February 2006 |
| NCT00342329 | Completed | Lupus Nephritis: Role of Environmental and Occupational Exposures | April 16, 2001 | March 7, 2007 | |
| NCT00371319 | Completed | Phase 4 | Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis | September 2005 | June 2014 |
| NCT00377637 | Completed | Phase 3 | A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis. | July 2005 | March 2010 |
| NCT00404794 | Completed | Phase 3 | A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis | November 2005 | October 2009 |
| NCT00423098 | Completed | Phase 2 | Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare | February 2007 | November 2009 |
| NCT00429377 | Completed | Phase 3 | Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study | June 2003 | |
| NCT00615173 | Completed | Phase 3 | Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis | July 2006 | September 2008 |
| NCT03174587 | Completed | Phase 1 | Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis | May 30, 2017 | August 19, 2019 |
| NCT03393013 | Completed | Phase 1/Phase 2 | A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis | February 20, 2018 | August 4, 2022 |
| NCT03385564 | Completed | Phase 2 | An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis | January 9, 2018 | July 27, 2021 |
| NCT00094380 | Completed | Phase 1/Phase 2 | Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) | September 2004 | January 2006 |
| NCT00125307 | Completed | Phase 4 | Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis | January 2004 | February 2008 |
| NCT00204022 | Completed | Phase 3 | Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis. | February 2001 | August 2011 |
| NCT00282347 | Completed | Phase 3 | A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis | January 2006 | January 2013 |
| NCT00298506 | Completed | N/A | Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V) | September 2005 | June 2009 |
| NCT02493101 | Completed | The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients | April 2013 | February 2015 | |
| NCT02547922 | Completed | Phase 2 | Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis | November 4, 2015 | January 18, 2021 |
| NCT02550652 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) | November 13, 2015 | August 2, 2023 |
| NCT02645565 | Completed | Phase 4 | Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis | December 2015 | December 2016 |
| NCT03687138 | Completed | Searching for Diagnostic/Prognostic Biomarkers in SLE With Renal Involvement by Proteomic Techniques | June 15, 2018 | February 28, 2022 | |
| NCT02770170 | Completed | Phase 2 | Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis | May 16, 2016 | August 18, 2020 |
| NCT03664908 | Completed | N/A | Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)? | September 1, 2018 | May 4, 2019 |
| NCT02949349 | Completed | Phase 2 | Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis | July 2015 | January 25, 2017 |
| NCT02949973 | Completed | Phase 2 | Aurinia Early Urinary Protein Reduction Predicts Response | June 2015 | February 17, 2017 |
| NCT03610516 | Completed | Phase 2 | Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. | September 12, 2018 | June 29, 2023 |
| NCT00001676 | Completed | Phase 1 | Cyclophosphamide and Fludarabine to Treat Lupus Nephritis | January 1998 | November 2002 |
| NCT03021499 | Completed | Phase 3 | Aurinia Renal Response in Active Lupus With Voclosporin | May 17, 2017 | October 10, 2019 |
| NCT03031925 | Completed | N/A | Detection of Annexin A2 in Systemic Lupus Erythematosus | May 9, 2017 | November 9, 2018 |
| NCT03597464 | Completed | Phase 3 | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin | September 29, 2019 | October 7, 2021 |
| NCT03180021 | Completed | Dynamic Imaging of Variation in Lupus Nephritis | March 13, 2018 | October 2, 2020 | |
| NCT00705367 | Completed | Phase 1 | Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg | August 2008 | July 2011 |
| NCT00709722 | Completed | Phase 1/Phase 2 | Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis | October 2003 | April 2007 |
| NCT00774852 | Completed | Phase 2 | Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis | November 2008 | June 2014 |
| NCT00876616 | Completed | N/A | Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis | April 2009 | February 2012 |
| NCT00881309 | Completed | N/A | To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis | March 2009 | May 2011 |
| NCT00935389 | Completed | N/A | Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria | April 2009 | May 2011 |
| NCT00976300 | Completed | Phase 2 | Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study | January 2002 | April 2009 |
| NCT01042457 | Completed | Phase 3 | Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis | May 2009 | December 2011 |
| NCT01056237 | Completed | N/A | Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis | February 2010 | June 2013 |
| NCT01085097 | Completed | Phase 2 | A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis | September 1, 2010 | October 24, 2012 |
| NCT01203709 | Completed | Phase 4 | Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis | August 2010 | February 2013 |
| NCT01206569 | Completed | Phase 4 | Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis | September 2010 | February 2012 |
| NCT01207297 | Completed | Phase 1 | Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis | March 2003 | June 2010 |
| NCT01273389 | Completed | Phase 2 | An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis | August 2011 | September 2013 |
| NCT05195086 | Completed | A Pharmacoeconomic Study Comparing the Use of Mycophenolate Mofetil or Cyclophosphamide as Induction Therapy in Lupus Nephritis Patients in Egypt | July 1, 2018 | June 5, 2021 | |
| NCT01410747 | Completed | A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations | April 10, 2007 | January 31, 2020 | |
| NCT01470183 | Completed | Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients | October 2011 | February 2013 | |
| NCT01580865 | Completed | N/A | Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis | May 2012 | March 2017 |
| NCT01639339 | Completed | Phase 3 | Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis | July 12, 2012 | March 12, 2020 |
| NCT04424602 | Completed | Phase 4 | Comparison between2 Drugs in Lupus Nephritis | April 5, 2021 | September 9, 2021 |
| NCT01731054 | Completed | Functional MRI in Lupus Nephritis | June 2013 | March 2015 | |
| NCT04318600 | Completed | Phase 1 | Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis | January 1, 2014 | January 1, 2019 |
| NCT00001789 | Completed | Phase 2 | BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis | June 1999 | May 2000 |
| NCT01845740 | Completed | Phase 1 | Phase Ib Study of SC Milatuzumab in SLE | January 2007 | June 2009 |
| NCT04266860 | Completed | N/A | Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients | March 1, 2012 | March 1, 2013 |
| NCT01931644 | Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions | July 2013 | April 2024 | |
| NCT02141672 | Completed | Phase 2 | AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) | June 2014 | January 2017 |
| NCT04146220 | Completed | Phase 4 | Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis | July 16, 2018 | September 30, 2019 |
| NCT00035308 | Completed | Phase 3 | Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease | December 2002 | |
| NCT02256150 | Completed | Phase 3 | A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis | November 2014 | March 2019 |
| NCT02260934 | Completed | Phase 2 | Rituximab and Belimumab for Lupus Nephritis | July 9, 2015 | February 8, 2019 |
| NCT04128579 | Completed | Phase 1 | Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis | October 1, 2019 | January 18, 2024 |
| NCT03921398 | Completed | Identifying New Therapeutic Targets for Lupus Treatment | June 18, 2019 | August 11, 2022 | |
| NCT03828071 | Completed | N/A | Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis | June 1, 2011 | December 1, 2018 |
| NCT02457221 | Completed | Phase 3 | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis | March 10, 2015 | September 10, 2018 |
| NCT05930314 | Enrolling by invitation | Early Phase 1 | CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus | June 19, 2023 | May 30, 2025 |
| NCT06113900 | Not yet recruiting | Phase 1/Phase 2 | Assessment of Safety and Efficacy of SGLT2is Among LN Patients | December 1, 2023 | January 30, 2025 |
| NCT06428539 | Not yet recruiting | T Regulatory Cells IN LUPUS NEPHRITIS | July 1, 2024 | August 1, 2025 | |
| NCT06375993 | Not yet recruiting | Phase 1 | A Phase 1 Study of ADI-001 in Lupus Nephritis | June 2024 | December 2027 |
| NCT04883619 | Not yet recruiting | Phase 2 | A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis | January 15, 2026 | February 28, 2028 |
| NCT06217107 | Not yet recruiting | N/A | Wellness & Workforce Solution for Lupus/Lupus Nephritis | June 2024 | November 2024 |
| NCT06350110 | Not yet recruiting | Phase 1/Phase 2 | Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) | November 10, 2024 | December 28, 2025 |
| NCT06155604 | Not yet recruiting | Phase 2 | SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease | December 1, 2023 | November 30, 2026 |
| NCT06228222 | Not yet recruiting | Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals. | January 25, 2024 | October 1, 2025 | |
| NCT05588830 | Not yet recruiting | The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study | October 20, 2022 | March 20, 2024 | |
| NCT05933213 | Not yet recruiting | Phase 4 | Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis | July 6, 2023 | December 2025 |
| NCT05566977 | Not yet recruiting | Phase 1 | Autologous Adoptive T Regulatory Cell Transfer in Autoimmune Diseases. | December 2022 | August 2024 |
| NCT06288308 | Not yet recruiting | Fibrinogen to Albumin Ratio (FAR) as a Predictive Biomarker for Lupus Nephritis (LN) | March 20, 2024 | December 2024 | |
| NCT06429800 | Not yet recruiting | Phase 1 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis | October 31, 2024 | April 2029 |
| NCT05964751 | Not yet recruiting | the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus Patients | August 1, 2023 | August 1, 2024 | |
| NCT06445127 | Recruiting | N/A | Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging) | May 7, 2024 | May 17, 2026 |
| NCT01802034 | Recruiting | Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID) | February 2013 | August 2025 | |
| NCT02226341 | Recruiting | Phase 4 | ACTHar in the Treatment of Lupus Nephritis | October 2014 | July 2024 |
| NCT03001973 | Recruiting | High Quality Evidence of Chinese Lupus Nephritis (HELP) | November 2013 | December 2026 | |
| NCT03673748 | Recruiting | Phase 2 | Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells | December 27, 2022 | July 2026 |
| NCT03791827 | Recruiting | Multicenter Registry of Pediatric Lupus Nephritis in China | December 1, 2018 | November 30, 2024 | |
| NCT03929887 | Recruiting | KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis | May 1, 2019 | December 31, 2028 | |
| NCT04449991 | Recruiting | N/A | Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis | January 5, 2022 | December 2028 |
| NCT04534647 | Recruiting | Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort | June 1, 2019 | June 1, 2025 | |
| NCT04564339 | Recruiting | Phase 2 | Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | December 11, 2020 | October 31, 2026 |
| NCT04645589 | Recruiting | Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis | March 16, 2021 | July 31, 2025 | |
| NCT04702256 | Recruiting | Phase 3 | Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF | December 9, 2021 | December 2031 |
| NCT04868838 | Recruiting | Phase 2 | Daratumumab to Treat Active Lupus Nephritis | April 20, 2021 | July 2026 |
| NCT05039619 | Recruiting | Phase 2 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | May 12, 2022 | March 13, 2029 |
| NCT05085418 | Recruiting | Early Phase 1 | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis | November 5, 2021 | November 5, 2024 |
| NCT05097989 | Recruiting | Phase 2 | Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | January 14, 2022 | June 30, 2026 |
| NCT05126277 | Recruiting | Phase 3 | Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | July 14, 2022 | July 15, 2030 |
| NCT05138133 | Recruiting | Phase 3 | Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | February 15, 2022 | July 7, 2028 |
| NCT05201469 | Recruiting | Phase 2 | VIBRANT: VIB4920 for Active Lupus Nephritis | May 16, 2022 | March 2027 |
| NCT05207358 | Recruiting | Phase 4 | Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis | March 2, 2022 | December 31, 2028 |
| NCT05268289 | Recruiting | Phase 2 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | August 10, 2022 | March 13, 2028 |
| NCT05337124 | Recruiting | A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US | March 25, 2022 | June 1, 2030 | |
| NCT05443516 | Recruiting | Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus | June 16, 2014 | December 31, 2032 | |
| NCT05495893 | Recruiting | Phase 4 | MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN | July 25, 2022 | May 31, 2025 |
| NCT05538208 | Recruiting | Phase 2 | The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | January 2024 | March 2026 |
| NCT05631717 | Recruiting | Phase 3 | The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN | October 1, 2022 | December 31, 2025 |
| NCT05680480 | Recruiting | Phase 2 | A Study of Telitacicept in Lupus Nephritis | April 17, 2023 | January 2025 |
| NCT05714670 | Recruiting | Phase 2 | The Effect of Curcumin on the Clinical Outcome of Pediatric Patients With Active Lupus Nephritis | April 1, 2023 | August 1, 2024 |
| NCT05732402 | Recruiting | Phase 1/Phase 2 | An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases | March 15, 2023 | January 2026 |
| NCT05780515 | Recruiting | Phase 1 | A Study of ANX009 in Adult Participants With Lupus Nephritis | August 9, 2022 | September 30, 2023 |
| NCT05781750 | Recruiting | Phase 2 | A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) | November 3, 2023 | July 2026 |
| NCT05798117 | Recruiting | Phase 1/Phase 2 | An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus | February 28, 2023 | October 9, 2026 |
| NCT05810948 | Recruiting | Phase 2 | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) | February 21, 2023 | October 2024 |
| NCT05845151 | Recruiting | N/A | Fibroblast Activating Protein Inhibitor PET Imaging in Lupus Nephritis | May 1, 2021 | April 30, 2024 |
| NCT05863936 | Recruiting | Phase 3 | Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis | April 1, 2023 | December 31, 2024 |
| NCT05916781 | Recruiting | Phase 4 | Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus | July 1, 2023 | July 31, 2026 |
| NCT05934149 | Recruiting | Lupus Landmark Study: A Prospective Registry and Biorepository | June 28, 2023 | December 2033 | |
| NCT05938725 | Recruiting | Phase 1/Phase 2 | A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | April 28, 2023 | August 2026 |
| NCT06058078 | Recruiting | Phase 2 | RY_SW01 Cell Injection Therapy in Active Lupus Nephritis | August 17, 2023 | December 31, 2028 |
| NCT06064929 | Recruiting | Phase 1 | A Study of Felzartamab in Participants With Lupus Nephritis | November 1, 2023 | May 2025 |
| NCT06121297 | Recruiting | Phase 1/Phase 2 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | February 16, 2024 | December 2027 |
| NCT06153095 | Recruiting | Phase 1/Phase 2 | A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE) | February 15, 2024 | February 2027 |
| NCT06167174 | Recruiting | Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis | December 5, 2023 | December 5, 2028 | |
| NCT06277427 | Recruiting | N/A | Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells | February 5, 2024 | January 31, 2027 |
| NCT06285279 | Recruiting | Phase 1 | FKC288 in Participants With Autoimmune Kidney Diseases | March 4, 2024 | December 31, 2028 |
| NCT06342960 | Recruiting | Phase 1/Phase 2 | A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-3) | December 1, 2022 | January 2029 |
| NCT06406205 | Recruiting | Phase 3 | A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | December 25, 2023 | June 2028 |
| NCT00447265 | Terminated | Phase 2 | Etanercept for the Treatment of Lupus Nephritis | February 2008 | March 2009 |
| NCT05232864 | Terminated | Phase 3 | Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis | August 22, 2022 | August 23, 2023 |
| NCT00626197 | Terminated | Phase 3 | A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) | February 15, 2008 | October 28, 2013 |
| NCT00573157 | Terminated | Phase 2/Phase 3 | The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis | December 2007 | April 2009 |
| NCT00425438 | Terminated | Phase 3 | A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis. | March 2007 | April 2008 |
| NCT01714817 | Terminated | Phase 3 | Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis | January 22, 2013 | May 30, 2018 |
| NCT01316133 | Terminated | Phase 4 | A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients | April 19, 2011 | April 8, 2016 |
| NCT04376827 | Terminated | Phase 2 | A Study of Guselkumab in Participants With Active Lupus Nephritis | September 15, 2020 | February 1, 2023 |
| NCT03920059 | Terminated | Phase 4 | Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis | August 20, 2019 | January 30, 2020 |
| NCT01342016 | Terminated | Phase 3 | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients | April 2011 | May 2013 |
| NCT01015456 | Terminated | Phase 3 | The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis | January 2010 | January 2013 |
| NCT03943147 | Terminated | Phase 2 | An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis | July 15, 2019 | September 17, 2021 |
| NCT00089804 | Terminated | Phase 3 | Study of LJP 394 in Lupus Patients With History of Renal Disease | October 2004 | February 2009 |
| NCT05540665 | Terminated | Phase 2 | Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN) | April 26, 2023 | January 4, 2024 |
| NCT01499355 | Terminated | Phase 2 | BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis | July 2012 | December 2015 |
| NCT02176486 | Terminated | Phase 1 | Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN) | June 9, 2014 | January 19, 2018 |
| NCT04181762 | Terminated | Phase 3 | Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis | July 7, 2020 | September 13, 2023 |
| NCT01369628 | Terminated | Phase 1 | Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil | June 2011 | |
| NCT02081183 | Terminated | Phase 3 | A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis | March 2006 | December 2008 |
| NCT01930890 | Terminated | Phase 2 | BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis | November 2013 | January 2016 |
| NCT01765842 | Terminated | Phase 3 | Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy | November 2012 | December 2015 |
| NCT00368264 | Terminated | Phase 2/Phase 3 | TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) | September 2006 | June 2009 |
| NCT04894695 | Unknown status | Urine Exosomes to Identify Biomarkers for LN | August 2, 2020 | August 31, 2021 | |
| NCT05082363 | Unknown status | The Expression Profile of New Complement Components in Childhood Lupus Nephritis | November 2021 | August 2022 | |
| NCT01226147 | Unknown status | Phase 2 | Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis | September 2010 | February 2013 |
| NCT05120882 | Unknown status | Epidemiology of Lupus Nephritis in Nephrology Unit in Assiut University Hospital | December 2021 | June 2022 | |
| NCT00659217 | Unknown status | Phase 1/Phase 2 | Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis | May 2008 | May 2010 |
| NCT05358652 | Unknown status | Precision Medicine in LN: A Multicenter Proof-of-concept Study for Histopathological Biomarkers Analysis in Renal Biopsy | October 15, 2021 | January 15, 2023 | |
| NCT03214731 | Unknown status | Phase 4 | Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis | January 16, 2019 | September 30, 2022 |
| NCT03201406 | Unknown status | Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease | June 20, 2017 | December 31, 2017 | |
| NCT03458156 | Unknown status | N/A | Umbilical Cord Mesenchymal Stem Cell Transplantation for Lupus Nephritis | January 2017 | January 2020 |
| NCT03526042 | Unknown status | N/A | Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis | September 10, 2017 | October 31, 2019 |
| NCT03580291 | Unknown status | Phase 2 | Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN) | August 1, 2018 | June 1, 2021 |
| NCT03054545 | Unknown status | N/A | Iguratimod as Treatment for Refractory Lupus Nephritis | May 8, 2017 | April 30, 2019 |
| NCT02954939 | Unknown status | N/A | The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis | March 1, 2017 | June 2021 |
| NCT02936375 | Unknown status | Phase 2 | The Iguratimod Effect on Lupus Nephritis (IGeLU) | September 7, 2017 | November 2021 |
| NCT02682407 | Unknown status | Phase 2 | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 | February 2016 | December 2020 |
| NCT02453997 | Unknown status | Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis | October 2012 | December 2019 | |
| NCT02435368 | Unknown status | The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear | April 2015 | March 2016 | |
| NCT03958851 | Unknown status | Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis | August 1, 2019 | January 2022 | |
| NCT02313974 | Unknown status | Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla) | January 2014 | November 2018 | |
| NCT04145687 | Unknown status | Phase 4 | Metformin In Prevention of Lupus Nephritis | November 2019 | June 2022 |
| NCT04218890 | Unknown status | TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis | April 1, 2020 | December 1, 2023 | |
| NCT04320797 | Unknown status | Urinary T Cell Biomarker for Prediction in Lupus Nephritis | July 30, 2019 | September 2022 | |
| NCT01673295 | Unknown status | Phase 3 | RING - Rituximab for Lupus Nephritis With Remission as a Goal | November 2014 | November 2016 |
| NCT01539902 | Unknown status | Phase 2 | Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis | February 2012 | May 2013 |
| NCT00569101 | Unknown status | Phase 2 | A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis | September 2007 | March 2008 |
| NCT04648059 | Unknown status | Epigenetics in Lupus Nephritis | December 1, 2020 | June 30, 2023 | |
| NCT04870359 | Unknown status | N/A | Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation | April 21, 2016 | March 31, 2023 |
| NCT04892212 | Unknown status | Phase 2/Phase 3 | Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis | June 30, 2021 | October 30, 2023 |
| NCT04924296 | Unknown status | Phase 2 | A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis | June 28, 2021 | September 3, 2022 |
| NCT00404157 | Withdrawn | Phase 3 | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g | ||
| NCT01288664 | Withdrawn | Phase 3 | Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis | January 2011 | December 2012 |
| NCT04369495 | Withdrawn | BAFF Levels and Lupus Nephritis (LN) | January 2021 | January 2023 | |
| NCT03859570 | Withdrawn | Phase 4 | Pentoxifylline in Lupus Nephritis | September 1, 2020 | December 2022 |
| NCT01169857 | Withdrawn | Phase 4 | Velcade for Proliferative Lupus Nephritis | August 2010 | December 2012 |
| NCT00539799 | Withdrawn | Phase 3 | Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis | ||
| NCT00908986 | Withdrawn | N/A | Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis | December 2008 | November 2009 |
| NCT05101447 | Withdrawn | Phase 2 | Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis | July 2023 | July 2024 |
| NCT01299922 | Withdrawn | Phase 3 | Clinical Trial Treatment in Lupus Nephritis | February 2011 | October 2014 |
- Disase is a (Disease Ontology)
- DOID:2921
- Cross Reference ID (Disease Ontology)
- GARD:10747
- Cross Reference ID (Disease Ontology)
- MESH:D008181
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008181